Analysis of U.S. Patent 5,384,113: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,384,113 cover?
U.S. Patent 5,384,113, granted on Jan. 24, 1995, lists inventors George K. Carter, David R. Garcia, and Robert J. Sabatelli. It is assigned to Eli Lilly and Company. The patent claims a specific method of synthesizing a class of compounds used as intermediates in pharmaceutical production, particularly for PDE5 inhibitors like sildenafil.
Core invention: The patent covers a process for preparing 1,2,3,4-tetrahydro-7-alkoxy-1-methyl-3-phenyl-5-quinolinol derivatives. These compounds serve as intermediates in the synthesis of active pharmaceutical ingredients (APIs) targeting erectile dysfunction.
What are the key claims?
The patent contains 12 claims. The most significant:
-
Claim 1: A process for preparing a compound of formula I, involving reacting a 2-aminobenzophenone derivative with a suitable amine in the presence of a catalytic amount of a strong acid, such as sulfuric acid, to produce a tetrahydroquinoline intermediate.
-
Claims 2-12: Variations on Claim 1, specifying different substituents, reaction conditions, solvents, and protective groups to broaden scope.
Scope of Claim 1
Claim 1 broadly covers a process involving a reaction between specific benzophenone derivatives and amines under acidic conditions to produce tetrahydroquinoline intermediates, which are essential in PDE5 inhibitor synthesis.
Dependent Claims
Dependent claims specify:
-
Different alkoxy substituents at the 7-position (e.g., methoxy, ethoxy).
-
Variations in the amine used, including secondary or primary amines.
-
Alternative reaction solvents and temperatures.
This breadth allows coverage of multiple synthetic routes for similar intermediates, impacting a wide range of PDE5 inhibitor manufacturing processes.
Patent landscape overview
Key patent holders and their portfolios
-
Eli Lilly and Company: Holds original claims, with subsequent patents building on this process.
-
Competitors: Patent filings focused on alternative synthetic methods, different intermediates, or formulations targeting PDE5 inhibitors, especially sildenafil, tadalafil, and vardenafil.
Related patents and innovation areas
-
Synthesis methods: Patents that describe alternative routes for tetrahydroquinoline intermediates, such as palladium-catalyzed couplings or novel cyclization techniques.
-
Intermediate protection: Patents covering protective groups and purification strategies to improve yield and purity.
-
Diverse PDE5 inhibitors: Patents covering structurally similar molecules, often overlapping in intermediate synthesis steps.
Patent expiration and freedom to operate
-
The original patent (5,384,113) expired on Jan. 24, 2012, 17 years after issuance.
-
Subsequent patents extending patent life or on specific formulations patent protection beyond original expiration.
-
Patent landscape indicates that competing companies may face freedom-to-operate issues mainly around intermediate synthesis if they rely solely on methods covered by this patent's claims.
Jurisdictional status
-
Filed and granted in the United States. International counterparts exist, especially in the Canada, Europe, and Asia, with varying durations.
-
Roadmaps for legal challenges or patent term extensions should consider jurisdictional differences.
Implications for R&D and patent strategy
-
Companies developing PDE5 inhibitors can design alternative synthetic pathways to circumvent patented processes, such as avoiding the specific intermediates covered here.
-
Patent expiration opens opportunities for generic manufacturing, provided no other active patents cover final compounds or formulations.
-
Patent landscape indicates ongoing innovation around intermediates and synthesis methods, often leading to additional patent protections.
Key Takeaways
-
U.S. Patent 5,384,113 protects a specific process for synthesizing tetrahydroquinoline intermediates integral to PDE5 inhibitors.
-
Its broad claims cover various substituents and reaction conditions, influencing generic entry and process development.
-
The patent expired in 2012, but related patents may still provide patent barriers depending on jurisdiction and claim scope.
-
Alternative synthesis methods and different intermediates are actively patented, indicating ongoing innovation in PDE5 inhibitor manufacturing.
-
R&D pathways should consider designing around the patent scope or exploring new intermediates to ensure freedom to operate.
FAQs
Q1: How does Patent 5,384,113 influence current PDE5 inhibitor manufacturing?
A: It initially covered key synthetic processes. Its expiration allows generic synthesis if no other active patents exist in the jurisdiction. Companies may still need to navigate newer patents covering specific intermediates or formulations.
Q2: Can I develop a different synthetic route for tetrahydroquinoline derivatives without infringing this patent?
A: Yes, if the new method does not use the specific steps claimed or if it differs sufficiently in reaction conditions, intermediates, or catalysts.
Q3: Are there patents that extend protection beyond 2012 for similar processes?
A: Yes. Patents filed thereafter, especially for improved intermediates or formulations, may extend overall patent coverage.
Q4: Does this patent cover final PDE5 inhibitor drugs like sildenafil?
A: No. It covers synthesis intermediates and processes, not the active pharmaceutical compounds themselves.
Q5: How should companies approach patent landscape analysis for PDE5 inhibitors?
A: They should identify active patents on intermediates, synthesis processes, formulations, and therapeutic claims, considering national and international jurisdictions for comprehensive freedom-to-operate assessments.
References
- U.S. Patent 5,384,113. (1995). Process for preparing tetrahydroquinoline intermediates. Patent and Trademark Office.
